Haleon director acquires company shares

Published 19/05/2025, 15:36
Haleon director acquires company shares

Haleon plc (LSE/NYSE:HLN), a leader in the consumer health industry, disclosed a transaction by a Person Discharging Managerial Responsibilities (PDMR) in a recent SEC filing. On Monday, the company reported that Bláthnaid Bergin, an Independent (LON:IOG) Non-Executive Director and PDMR, purchased ordinary shares.

The transaction took place on Thursday, involving the acquisition of 6,145 Haleon ordinary shares at a price of £4.0427 per share. This purchase was conducted on the London Stock Exchange (LON:LSEG) (XLON). The company provided the identification code for the shares as GB00BMX86B70.

The filing stated that this was an initial notification and did not aggregate with any other transactions. It was a single transaction with no further aggregated information provided. The disclosure aligns with the UK Market Abuse Regulation requirements, ensuring transparency in transactions by company insiders.

Haleon’s portfolio includes well-known brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren. The company focuses on products across six major categories: Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health and Other.

This financial activity comes as part of the company’s commitment to transparency and regulatory compliance, as detailed in the SEC Form 6-K. The filing was signed by Amanda Mellor, Company Secretary, on behalf of Haleon plc. The information is based on a press release statement and reflects the company’s adherence to legal reporting standards.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.